# Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

> **NCT05740943** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Stage III NSCLC
- Surgery

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT05740943
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-04-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740943, "Induction Lorlatinib in Stage III Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05740943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*